JP2011500855A5

JP2011500855A5 -

Download PDF

Info

Publication number: JP2011500855A5
Authority: JP; Japan
Prior art keywords: substituted; unsubstituted; compound; alkyl; salt
Prior art date: 2008-10-27
Legal status : Granted

Application number

JP2010531322A

Other languages

English (en)

Japanese (ja)

Other versions

JP2011500855A (ja

JP5665543B2 (ja

Filing date

2008-10-27

Publication date

2012-02-16

2007-10-25 Priority claimed from RU2007139634/04A external-priority patent/RU2007139634A/ru

2008-10-27 Application filed filed Critical

2011-01-06 Publication of JP2011500855A publication Critical patent/JP2011500855A/ja

2012-02-16 Publication of JP2011500855A5 publication Critical patent/JP2011500855A5/ja

2015-02-04 Application granted granted Critical

2015-02-04 Publication of JP5665543B2 publication Critical patent/JP5665543B2/ja

Status Expired - Fee Related legal-status Critical Current

2028-10-27 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims description 1205
125000000217 alkyl group Chemical group 0.000 claims description 263
-1 perhaloalkyl Chemical group 0.000 claims description 255
125000005843 halogen group Chemical group 0.000 claims description 225
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 204
125000000623 heterocyclic group Chemical group 0.000 claims description 175
150000003839 salts Chemical class 0.000 claims description 170
125000001072 heteroaryl group Chemical group 0.000 claims description 163
125000003118 aryl group Chemical group 0.000 claims description 148
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 129
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 121
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 110
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 101
125000003545 alkoxy group Chemical group 0.000 claims description 91
125000004093 cyano group Chemical group *C#N 0.000 claims description 81
102000005962 receptors Human genes 0.000 claims description 76
108020003175 receptors Proteins 0.000 claims description 76
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 74
229910052799 carbon Inorganic materials 0.000 claims description 72
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 70
125000005102 carbonylalkoxy group Chemical group 0.000 claims description 66
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 59
125000000753 cycloalkyl group Chemical group 0.000 claims description 58
125000004076 pyridyl group Chemical group 0.000 claims description 57
125000003710 aryl alkyl group Chemical group 0.000 claims description 53
125000001309 chloro group Chemical group Cl* 0.000 claims description 52
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 51
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 50
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 50
102000015554 Dopamine receptor Human genes 0.000 claims description 50
108050004812 Dopamine receptor Proteins 0.000 claims description 50
125000002252 acyl group Chemical group 0.000 claims description 49
208000010877 cognitive disease Diseases 0.000 claims description 48
125000004104 aryloxy group Chemical group 0.000 claims description 47
239000002858 neurotransmitter agent Substances 0.000 claims description 47
125000004001 thioalkyl group Chemical group 0.000 claims description 45
125000004442 acylamino group Chemical group 0.000 claims description 43
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 43
108060003345 Adrenergic Receptor Proteins 0.000 claims description 42
102000017910 Adrenergic receptor Human genes 0.000 claims description 42
125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 42
238000011282 treatment Methods 0.000 claims description 39
125000005589 carbonylalkylenealkoxy group Chemical group 0.000 claims description 38
125000001153 fluoro group Chemical group F* 0.000 claims description 38
150000003573 thiols Chemical class 0.000 claims description 38
102000000543 Histamine Receptors Human genes 0.000 claims description 37
108010002059 Histamine Receptors Proteins 0.000 claims description 37
229910052757 nitrogen Inorganic materials 0.000 claims description 37
125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 36
125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 35
210000002569 neuron Anatomy 0.000 claims description 31
125000004423 acyloxy group Chemical group 0.000 claims description 30
125000003342 alkenyl group Chemical group 0.000 claims description 28
125000000304 alkynyl group Chemical group 0.000 claims description 27
125000000392 cycloalkenyl group Chemical group 0.000 claims description 27
208000028017 Psychotic disease Diseases 0.000 claims description 26
208000028698 Cognitive impairment Diseases 0.000 claims description 25
230000001404 mediated effect Effects 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 22
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 21
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 19
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 18
230000001537 neural effect Effects 0.000 claims description 17
125000003386 piperidinyl group Chemical group 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 16
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 12
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 9
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
125000001715 oxadiazolyl group Chemical group 0.000 claims description 6
125000000335 thiazolyl group Chemical group 0.000 claims description 6
125000001425 triazolyl group Chemical group 0.000 claims description 6
125000001475 halogen functional group Chemical group 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
125000004950 trifluoroalkyl group Chemical group 0.000 claims description 3
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000001188 haloalkyl group Chemical group 0.000 claims description 2
150000003222 pyridines Chemical class 0.000 claims description 2
230000027455 binding Effects 0.000 description 134
230000000694 effects Effects 0.000 description 91
229910052739 hydrogen Inorganic materials 0.000 description 78
239000003446 ligand Substances 0.000 description 77
238000003556 assay Methods 0.000 description 73
239000001257 hydrogen Substances 0.000 description 72
238000000034 method Methods 0.000 description 62
230000014511 neuron projection development Effects 0.000 description 59
201000010099 disease Diseases 0.000 description 49
229940075993 receptor modulator Drugs 0.000 description 46
208000035475 disorder Diseases 0.000 description 45
150000002431 hydrogen Chemical class 0.000 description 42
201000000980 schizophrenia Diseases 0.000 description 35
208000024891 symptom Diseases 0.000 description 34
239000000556 agonist Substances 0.000 description 32
102100040368 5-hydroxytryptamine receptor 6 Human genes 0.000 description 30
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 30
102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 29
101710150235 5-hydroxytryptamine receptor 6 Proteins 0.000 description 28
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 28
239000005557 antagonist Substances 0.000 description 28
125000003107 substituted aryl group Chemical group 0.000 description 27
125000004193 piperazinyl group Chemical group 0.000 description 22
125000001424 substituent group Chemical group 0.000 description 22
230000007074 memory dysfunction Effects 0.000 description 21
230000000561 anti-psychotic effect Effects 0.000 description 20
230000001149 cognitive effect Effects 0.000 description 20
125000000547 substituted alkyl group Chemical group 0.000 description 20
230000005764 inhibitory process Effects 0.000 description 19
101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 18
125000005017 substituted alkenyl group Chemical group 0.000 description 18
125000004426 substituted alkynyl group Chemical group 0.000 description 18
208000024827 Alzheimer disease Diseases 0.000 description 17
230000000875 corresponding effect Effects 0.000 description 17
JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 16
239000012453 solvate Substances 0.000 description 16
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 15
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 15
102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 description 15
101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 description 15
208000027061 mild cognitive impairment Diseases 0.000 description 15
230000001737 promoting effect Effects 0.000 description 15
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 14
230000015654 memory Effects 0.000 description 14
125000004433 nitrogen atom Chemical group N* 0.000 description 14
125000003373 pyrazinyl group Chemical group 0.000 description 14
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
102000004108 Neurotransmitter Receptors Human genes 0.000 description 13
108090000590 Neurotransmitter Receptors Proteins 0.000 description 13
230000032683 aging Effects 0.000 description 13
230000001713 cholinergic effect Effects 0.000 description 13
208000014674 injury Diseases 0.000 description 13
208000021075 Creatine deficiency syndrome Diseases 0.000 description 12
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 12
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 12
201000008609 cerebral creatine deficiency syndrome Diseases 0.000 description 12
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
239000000654 additive Substances 0.000 description 11
210000004556 brain Anatomy 0.000 description 11
230000006378 damage Effects 0.000 description 11
229910052731 fluorine Inorganic materials 0.000 description 11
125000000719 pyrrolidinyl group Chemical group 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
208000020431 spinal cord injury Diseases 0.000 description 11
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
208000023105 Huntington disease Diseases 0.000 description 10
208000018737 Parkinson disease Diseases 0.000 description 10
208000030886 Traumatic Brain injury Diseases 0.000 description 10
208000027418 Wounds and injury Diseases 0.000 description 10
230000009286 beneficial effect Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 10
208000013403 hyperactivity Diseases 0.000 description 10
230000035772 mutation Effects 0.000 description 10
230000004766 neurogenesis Effects 0.000 description 10
230000009529 traumatic brain injury Effects 0.000 description 10
102100032509 Histamine H1 receptor Human genes 0.000 description 9
101001016841 Homo sapiens Histamine H1 receptor Proteins 0.000 description 9
241000700159 Rattus Species 0.000 description 9
230000000996 additive effect Effects 0.000 description 9
230000006399 behavior Effects 0.000 description 9
230000006870 function Effects 0.000 description 9
206010027175 memory impairment Diseases 0.000 description 9
230000004770 neurodegeneration Effects 0.000 description 9
230000000750 progressive effect Effects 0.000 description 9
125000000168 pyrrolyl group Chemical group 0.000 description 9
210000000225 synapse Anatomy 0.000 description 9
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
230000003920 cognitive function Effects 0.000 description 8
238000002648 combination therapy Methods 0.000 description 8
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
210000002161 motor neuron Anatomy 0.000 description 8
210000003205 muscle Anatomy 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
206010003805 Autism Diseases 0.000 description 7
208000020706 Autistic disease Diseases 0.000 description 7
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
208000006011 Stroke Diseases 0.000 description 7
230000002159 abnormal effect Effects 0.000 description 7
230000003185 calcium uptake Effects 0.000 description 7
230000034994 death Effects 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
208000002780 macular degeneration Diseases 0.000 description 7
238000003522 neurite outgrowth assay Methods 0.000 description 7
208000015122 neurodegenerative disease Diseases 0.000 description 7
230000008447 perception Effects 0.000 description 7
208000033808 peripheral neuropathy Diseases 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
229940076279 serotonin Drugs 0.000 description 7
125000005415 substituted alkoxy group Chemical group 0.000 description 7
210000003568 synaptosome Anatomy 0.000 description 7
125000004568 thiomorpholinyl group Chemical group 0.000 description 7
230000008448 thought Effects 0.000 description 7
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
241000282465 Canis Species 0.000 description 6
208000032131 Diabetic Neuropathies Diseases 0.000 description 6
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
229960004170 clozapine Drugs 0.000 description 6
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 6
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
230000007423 decrease Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 6
201000006417 multiple sclerosis Diseases 0.000 description 6
230000000508 neurotrophic effect Effects 0.000 description 6
125000006574 non-aromatic ring group Chemical group 0.000 description 6
125000004043 oxo group Chemical group O=* 0.000 description 6
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
229960002646 scopolamine Drugs 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 5
108091005435 5-HT6 receptors Proteins 0.000 description 5
201000004384 Alopecia Diseases 0.000 description 5
208000019901 Anxiety disease Diseases 0.000 description 5
208000020925 Bipolar disease Diseases 0.000 description 5
208000001640 Fibromyalgia Diseases 0.000 description 5
208000035895 Guillain-Barré syndrome Diseases 0.000 description 5
206010049567 Miller Fisher syndrome Diseases 0.000 description 5
208000026935 allergic disease Diseases 0.000 description 5
239000000739 antihistaminic agent Substances 0.000 description 5
230000036506 anxiety Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
229940125878 compound 36 Drugs 0.000 description 5
239000000835 fiber Substances 0.000 description 5
125000002541 furyl group Chemical group 0.000 description 5
125000004475 heteroaralkyl group Chemical group 0.000 description 5
229960001340 histamine Drugs 0.000 description 5
230000001771 impaired effect Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
230000003278 mimic effect Effects 0.000 description 5
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
210000002241 neurite Anatomy 0.000 description 5
230000016273 neuron death Effects 0.000 description 5
201000001119 neuropathy Diseases 0.000 description 5
230000007823 neuropathy Effects 0.000 description 5
229920000728 polyester Polymers 0.000 description 5
230000001953 sensory effect Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 4
YBQNZVZKRIUIEE-UHFFFAOYSA-N 2-ethyl-5-(2-phenylethyl)-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(CC)CCC2=C1C1=CC=CC=C1N2CCC1=CC=CC=C1 YBQNZVZKRIUIEE-UHFFFAOYSA-N 0.000 description 4
125000001054 5 membered carbocyclic group Chemical group 0.000 description 4
108091005436 5-HT7 receptors Proteins 0.000 description 4
125000004008 6 membered carbocyclic group Chemical group 0.000 description 4
125000001960 7 membered carbocyclic group Chemical group 0.000 description 4
102000003678 AMPA Receptors Human genes 0.000 description 4
108090000078 AMPA Receptors Proteins 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
230000003281 allosteric effect Effects 0.000 description 4
125000006598 aminocarbonylamino group Chemical group 0.000 description 4
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
230000003542 behavioural effect Effects 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
125000002837 carbocyclic group Chemical group 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
230000002490 cerebral effect Effects 0.000 description 4
230000037410 cognitive enhancement Effects 0.000 description 4
210000003618 cortical neuron Anatomy 0.000 description 4
239000013078 crystal Substances 0.000 description 4
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
125000002883 imidazolyl group Chemical group 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000002427 irreversible effect Effects 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
210000000653 nervous system Anatomy 0.000 description 4
230000003955 neuronal function Effects 0.000 description 4
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
208000020016 psychiatric disease Diseases 0.000 description 4
210000000449 purkinje cell Anatomy 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
238000012360 testing method Methods 0.000 description 4
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 4
125000001544 thienyl group Chemical group 0.000 description 4
150000003852 triazoles Chemical class 0.000 description 4
230000004584 weight gain Effects 0.000 description 4
235000019786 weight gain Nutrition 0.000 description 4
DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 3
229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 3
101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 3
102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 3
NJIAKNWTIVDSDA-FQEVSTJZSA-N 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-n-[[(2s)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine Chemical compound C1CN(S(=O)(=O)C)CCC1C1=CC=C(C=2N=C(NC[C@H]3OCCNC3)C3=NC=CN=C3C=2)C=C1 NJIAKNWTIVDSDA-FQEVSTJZSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
101150051188 Adora2a gene Proteins 0.000 description 3
101150078577 Adora2b gene Proteins 0.000 description 3
108010011485 Aspartame Proteins 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
208000002177 Cataract Diseases 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
229930091371 Fructose Natural products 0.000 description 3
239000005715 Fructose Substances 0.000 description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
239000005913 Maltodextrin Substances 0.000 description 3
229920002774 Maltodextrin Polymers 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
108010025020 Nerve Growth Factor Proteins 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
206010036105 Polyneuropathy Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
206010039897 Sedation Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000021017 Weight Gain Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
206010064930 age-related macular degeneration Diseases 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
229940125715 antihistaminic agent Drugs 0.000 description 3
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
235000010357 aspartame Nutrition 0.000 description 3
239000000605 aspartame Substances 0.000 description 3
229960003438 aspartame Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
230000019771 cognition Effects 0.000 description 3
230000006999 cognitive decline Effects 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000006866 deterioration Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
229960003638 dopamine Drugs 0.000 description 3
201000006321 fundus dystrophy Diseases 0.000 description 3
208000024963 hair loss Diseases 0.000 description 3
230000003676 hair loss Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
229940035034 maltodextrin Drugs 0.000 description 3
230000006386 memory function Effects 0.000 description 3
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 3
229960000582 mepyramine Drugs 0.000 description 3
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
125000002757 morpholinyl group Chemical group 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
230000007824 polyneuropathy Effects 0.000 description 3
210000002243 primary neuron Anatomy 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
125000000714 pyrimidinyl group Chemical group 0.000 description 3
238000007634 remodeling Methods 0.000 description 3
230000036280 sedation Effects 0.000 description 3
241000894007 species Species 0.000 description 3
125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
230000009747 swallowing Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000008733 trauma Effects 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
210000004885 white matter Anatomy 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 2
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
208000036640 Asperger disease Diseases 0.000 description 2
201000006062 Asperger syndrome Diseases 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
208000014644 Brain disease Diseases 0.000 description 2
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
125000006414 CCl Chemical group ClC* 0.000 description 2
206010012239 Delusion Diseases 0.000 description 2
208000031124 Dementia Alzheimer type Diseases 0.000 description 2
208000012239 Developmental disease Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000003164 Diplopia Diseases 0.000 description 2
229920002148 Gellan gum Polymers 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
102000003834 Histamine H1 Receptors Human genes 0.000 description 2
108090000110 Histamine H1 Receptors Proteins 0.000 description 2
102000003710 Histamine H2 Receptors Human genes 0.000 description 2
108090000050 Histamine H2 Receptors Proteins 0.000 description 2
102000004384 Histamine H3 receptors Human genes 0.000 description 2
108090000981 Histamine H3 receptors Proteins 0.000 description 2
102000016252 Huntingtin Human genes 0.000 description 2
108050004784 Huntingtin Proteins 0.000 description 2
102000009032 Imidazoline Receptors Human genes 0.000 description 2
108010049134 Imidazoline Receptors Proteins 0.000 description 2
208000032578 Inherited retinal disease Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000016604 Lyme disease Diseases 0.000 description 2
208000026139 Memory disease Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
206010028289 Muscle atrophy Diseases 0.000 description 2
206010028372 Muscular weakness Diseases 0.000 description 2
102000006386 Myelin Proteins Human genes 0.000 description 2
108010083674 Myelin Proteins Proteins 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
206010034719 Personality change Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000008348 Post-Concussion Syndrome Diseases 0.000 description 2
108010050254 Presenilins Proteins 0.000 description 2
208000032319 Primary lateral sclerosis Diseases 0.000 description 2
208000032430 Retinal dystrophy Diseases 0.000 description 2
208000006289 Rett Syndrome Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
238000011226 adjuvant chemotherapy Methods 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
231100000360 alopecia Toxicity 0.000 description 2
102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 2
108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 2
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 2
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
101150031224 app gene Proteins 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000003935 attention Effects 0.000 description 2
208000029560 autism spectrum disease Diseases 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
210000004227 basal ganglia Anatomy 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
230000030833 cell death Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000007910 chewable tablet Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000037411 cognitive enhancing Effects 0.000 description 2
238000004891 communication Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
231100000868 delusion Toxicity 0.000 description 2
210000001787 dendrite Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
125000004188 dichlorophenyl group Chemical group 0.000 description 2
125000004212 difluorophenyl group Chemical group 0.000 description 2
125000005805 dimethoxy phenyl group Chemical group 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
208000029444 double vision Diseases 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
210000000744 eyelid Anatomy 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
235000010492 gellan gum Nutrition 0.000 description 2
239000000216 gellan gum Substances 0.000 description 2
239000003349 gelling agent Substances 0.000 description 2
239000003979 granulating agent Substances 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000017532 inherited retinal dystrophy Diseases 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
230000010354 integration Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
125000002346 iodo group Chemical group I* 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
239000008101 lactose Substances 0.000 description 2
201000010901 lateral sclerosis Diseases 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
230000004065 mitochondrial dysfunction Effects 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
230000004898 mitochondrial function Effects 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
230000020763 muscle atrophy Effects 0.000 description 2
201000000585 muscular atrophy Diseases 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
210000005012 myelin Anatomy 0.000 description 2
230000010807 negative regulation of binding Effects 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
210000000715 neuromuscular junction Anatomy 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
210000004248 oligodendroglia Anatomy 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000003989 repetitive behavior Effects 0.000 description 2
208000013406 repetitive behavior Diseases 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
230000035807 sensation Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
230000008454 sleep-wake cycle Effects 0.000 description 2
230000003997 social interaction Effects 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
125000003003 spiro group Chemical group 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000012549 training Methods 0.000 description 2
125000004360 trifluorophenyl group Chemical group 0.000 description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000000230 xanthan gum Substances 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
235000010493 xanthan gum Nutrition 0.000 description 2
229940082509 xanthan gum Drugs 0.000 description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
ALYCEQJIRFYVGE-VASSOYJASA-N (2s,12bs)-1',3'-dimethylspiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,4'-1,3-diazinane]-2'-one;hydrochloride Chemical compound Cl.CN1C(=O)N(C)CC[C@@]11C[C@H]2C(OC=3C4=CC=CC=3)=C4CCN2CC1 ALYCEQJIRFYVGE-VASSOYJASA-N 0.000 description 1
JLSKKNMEDAIQEI-UHFFFAOYSA-N (4-hydroxyphenyl)-[5-[(4-hydroxyphenyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]methanone Chemical compound C1=CC(O)=CC=C1CN1C2=CC=CC=C2C2=C1CCN(C(=O)C=1C=CC(O)=CC=1)C2 JLSKKNMEDAIQEI-UHFFFAOYSA-N 0.000 description 1
WYZFLCYTROCEOJ-UHFFFAOYSA-N 1h-pyrido[4,3-b]indole Chemical compound C1=CC=CC2=C3CN=CC=C3N=C21 WYZFLCYTROCEOJ-UHFFFAOYSA-N 0.000 description 1
XRURIYKULNUPMM-UHFFFAOYSA-N 2,8-dimethyl-5-(2-piperidin-1-ylethyl)-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCN1CCCCC1 XRURIYKULNUPMM-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
DSIPZULXRXDEAF-UHFFFAOYSA-N 2-ethyl-5-pyridin-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(CC)CCC2=C1C1=CC=CC=C1N2C1=CC=CC=N1 DSIPZULXRXDEAF-UHFFFAOYSA-N 0.000 description 1
IVGJTPHLXVSPPT-UHFFFAOYSA-N 2-methyl-5-(2-pyrrolidin-1-ylethyl)-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CCN1CCCC1 IVGJTPHLXVSPPT-UHFFFAOYSA-N 0.000 description 1
125000004011 3 membered carbocyclic group Chemical group 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000001845 4 membered carbocyclic group Chemical group 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
229940124801 5-HT6 antagonist Drugs 0.000 description 1
ONURMSJSEIGQBU-UHFFFAOYSA-N 5-[(2,4-dimethylphenyl)methyl]-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1=CC=C(C)C=C1C ONURMSJSEIGQBU-UHFFFAOYSA-N 0.000 description 1
SLQQSRRBUVHVQA-UHFFFAOYSA-N 5-[(4-chlorophenyl)methyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(Cl)C=C1 SLQQSRRBUVHVQA-UHFFFAOYSA-N 0.000 description 1
NEQQANSMYHEQOX-UHFFFAOYSA-N 5-[2-(azepan-1-yl)ethyl]-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCN1CCCCCC1 NEQQANSMYHEQOX-UHFFFAOYSA-N 0.000 description 1
102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
HUEGAGAAEGUZHN-UHFFFAOYSA-N 7-chloro-5-[(4-chlorophenyl)methyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC=C(Cl)C=C1N2CC1=CC=C(Cl)C=C1 HUEGAGAAEGUZHN-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
PQHBNZYUSMDSRJ-UHFFFAOYSA-N 8-bromo-2-methyl-5-[1-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1=2CCN(C)CC=2C2=CC(Br)=CC=C2N1C(C)C1=CC=C(C)N=C1 PQHBNZYUSMDSRJ-UHFFFAOYSA-N 0.000 description 1
QNJICKXJFOBJOF-UHFFFAOYSA-N 8-chloro-2-methyl-5-[1-(6-methylpyridin-2-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1=2CCN(C)CC=2C2=CC(Cl)=CC=C2N1C(C)C1=CC=CC(C)=N1 QNJICKXJFOBJOF-UHFFFAOYSA-N 0.000 description 1
PTSDCSIDVPXWAO-UHFFFAOYSA-N 8-chloro-5-[(4-chlorophenyl)methyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC1=CC=C(Cl)C=C1 PTSDCSIDVPXWAO-UHFFFAOYSA-N 0.000 description 1
HRNCHNDOYXHVHX-UHFFFAOYSA-N 8-chloro-5-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=C(Cl)C=C2C2=C1CCN(C)C2 HRNCHNDOYXHVHX-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
108010060159 Apolipoprotein E4 Proteins 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000025978 Athletic injury Diseases 0.000 description 1
206010061666 Autonomic neuropathy Diseases 0.000 description 1
208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010006542 Bulbar palsy Diseases 0.000 description 1
JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
206010007747 Cataract congenital Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
206010008748 Chorea Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010009696 Clumsiness Diseases 0.000 description 1
208000006992 Color Vision Defects Diseases 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
206010010219 Compulsions Diseases 0.000 description 1
102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
101150104779 HTR2A gene Proteins 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
102100032499 Histamine H2 receptor Human genes 0.000 description 1
229940122236 Histamine receptor antagonist Drugs 0.000 description 1
101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
101001016827 Homo sapiens Histamine H2 receptor Proteins 0.000 description 1
101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
101001109698 Homo sapiens Nuclear receptor subfamily 4 group A member 2 Proteins 0.000 description 1
101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
101150056637 Hrh2 gene Proteins 0.000 description 1
101150013372 Htr2c gene Proteins 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000015592 Involuntary movements Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
201000002832 Lewy body dementia Diseases 0.000 description 1
VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
208000012583 Menkes disease Diseases 0.000 description 1
102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
102000008763 Neurofilament Proteins Human genes 0.000 description 1
108010088373 Neurofilament Proteins Proteins 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
208000016113 North Carolina macular dystrophy Diseases 0.000 description 1
102100022676 Nuclear receptor subfamily 4 group A member 2 Human genes 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
208000014723 Oculomotor Nerve disease Diseases 0.000 description 1
206010061323 Optic neuropathy Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000034247 Pattern dystrophy Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000028361 Penetrating Head injury Diseases 0.000 description 1
241000206607 Porphyra umbilicalis Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
208000007014 Retinitis pigmentosa Diseases 0.000 description 1
206010040021 Sensory abnormalities Diseases 0.000 description 1
206010040030 Sensory loss Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000027073 Stargardt disease Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102000019355 Synuclein Human genes 0.000 description 1
108050006783 Synuclein Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
206010043431 Thinking abnormal Diseases 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
206010046298 Upper motor neurone lesion Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
208000014769 Usher Syndromes Diseases 0.000 description 1
241000256856 Vespidae Species 0.000 description 1
208000018839 Wilson disease Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
229940126157 adrenergic receptor agonist Drugs 0.000 description 1
230000003679 aging effect Effects 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
229910001413 alkali metal ion Inorganic materials 0.000 description 1
125000003302 alkenyloxy group Chemical group 0.000 description 1
125000005133 alkynyloxy group Chemical group 0.000 description 1
239000013566 allergen Substances 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
230000003712 anti-aging effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
201000007201 aphasia Diseases 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000037007 arousal Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
210000002453 autonomic neuron Anatomy 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
125000003725 azepanyl group Chemical group 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
231100000871 behavioral problem Toxicity 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
210000001775 bruch membrane Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000010267 cellular communication Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000004637 cellular stress Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
208000012601 choreatic disease Diseases 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
230000036992 cognitive tasks Effects 0.000 description 1
201000007254 color blindness Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
208000006623 congenital stationary night blindness Diseases 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
229960003176 cyclothiazide Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
125000004982 dihaloalkyl group Chemical group 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
108010017146 dopamine D2L receptor Proteins 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
210000003981 ectoderm Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000003256 environmental substance Substances 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000008921 facial expression Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000020932 food allergy Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000035784 germination Effects 0.000 description 1
210000004884 grey matter Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000003386 histamine H2 receptor agonist Substances 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000037417 hyperactivation Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000010365 information processing Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
239000002919 insect venom Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
208000020658 intracerebral hemorrhage Diseases 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
230000008449 language Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
229950002454 lysergide Drugs 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
208000038015 macular disease Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000018984 mastication Effects 0.000 description 1
238000010077 mastication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000003924 mental process Effects 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000006384 methylpyridyl group Chemical group 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000007625 mitochondrial abnormality Effects 0.000 description 1
201000005518 mononeuropathy Diseases 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
208000030194 mouth disease Diseases 0.000 description 1
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
210000003007 myelin sheath Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
210000005157 neural retina Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
238000010984 neurological examination Methods 0.000 description 1
208000018360 neuromuscular disease Diseases 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
208000020911 optic nerve disease Diseases 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
102000045222 parkin Human genes 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
208000027232 peripheral nervous system disease Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
108091008695 photoreceptors Proteins 0.000 description 1
208000024335 physical disease Diseases 0.000 description 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
230000001144 postural effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
201000002241 progressive bulbar palsy Diseases 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000011814 protection agent Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
BLGXFZZNTVWLAY-DIRVCLHFSA-N rauwolscine Chemical compound C1=CC=C2C(CCN3C[C@H]4CC[C@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-DIRVCLHFSA-N 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
210000003583 retinal pigment epithelium Anatomy 0.000 description 1
238000007665 sagging Methods 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000001044 sensory neuron Anatomy 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
229940121356 serotonin receptor antagonist Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000006403 short-term memory Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000000273 spinal nerve root Anatomy 0.000 description 1
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000006387 trifluoromethyl pyridyl group Chemical group 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1

JP2010531322A 2007-10-25 2008-10-27 新規四環系化合物 Expired - Fee Related JP5665543B2 (ja)